NasdaqGS - Nasdaq Real Time Price USD

MacroGenics, Inc. (MGNX)

16.38 +0.97 (+6.29%)
As of 12:30 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
57,193.00
57,193.00
150,018.00
75,643.00
97,764.00
Cost of Revenue
8,222.00
8,222.00
7,384.00
2,651.00
--
Gross Profit
48,971.00
48,971.00
142,634.00
72,992.00
97,764.00
Operating Expense
217,215.00
217,215.00
264,052.00
275,787.00
228,824.00
Operating Income
-168,244.00
-168,244.00
-121,418.00
-202,795.00
-131,060.00
Net Non Operating Interest Income Expense
8,256.00
8,256.00
1,660.00
680.00
--
Other Income Expense
150,930.00
150,930.00
1,660.00
680.00
1,321.00
Pretax Income
-9,058.00
-9,058.00
-119,758.00
-202,115.00
-129,739.00
Net Income Common Stockholders
-9,058.00
-9,058.00
-119,758.00
-202,115.00
-129,739.00
Diluted NI Available to Com Stockholders
-9,058.00
-9,058.00
-119,758.00
-202,115.00
-129,739.00
Basic EPS
-0.15
--
-1.95
-3.37
-2.47
Diluted EPS
-0.15
--
-1.95
-3.37
-2.47
Basic Average Shares
61,929.20
--
61,433.12
59,944.72
52,442.39
Diluted Average Shares
61,929.20
--
61,433.12
59,944.72
52,442.39
Total Operating Income as Reported
-168,244.00
-168,244.00
-121,418.00
-202,795.00
-131,060.00
Total Expenses
225,437.00
225,437.00
271,436.00
278,438.00
228,824.00
Net Income from Continuing & Discontinued Operation
-9,058.00
-9,058.00
-119,758.00
-202,115.00
-129,739.00
Normalized Income
-159,988.00
-159,988.00
-119,758.00
-202,115.00
-129,739.00
Interest Income
9,686.00
9,686.00
1,660.00
680.00
--
Interest Expense
1,430.00
1,430.00
--
--
--
Net Interest Income
8,256.00
8,256.00
1,660.00
680.00
--
EBIT
-7,628.00
-7,628.00
-119,758.00
-202,115.00
-131,060.00
EBITDA
2,017.00
2,017.00
-107,893.00
-190,857.00
-119,103.00
Reconciled Cost of Revenue
8,222.00
8,222.00
7,384.00
2,651.00
--
Reconciled Depreciation
9,645.00
9,645.00
11,865.00
11,258.00
11,957.00
Net Income from Continuing Operation Net Minority Interest
-9,058.00
-9,058.00
-119,758.00
-202,115.00
-129,739.00
Total Unusual Items Excluding Goodwill
150,930.00
150,930.00
--
--
--
Total Unusual Items
150,930.00
150,930.00
--
--
--
Normalized EBITDA
-148,913.00
-148,913.00
-107,893.00
-190,857.00
-119,103.00
12/31/2020 - 10/10/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PEPG PepGen Inc.
11.38
-0.13%
 
MRSN Mersana Therapeutics, Inc.
3.2350
+2.70%
 
ENTA Enanta Pharmaceuticals, Inc.
13.37
-0.56%
 
STRO Sutro Biopharma, Inc.
3.8050
+0.93%
 
XNCR Xencor, Inc.
18.50
+1.59%
 
ACLX Arcellx, Inc.
55.39
+6.51%
 
CTMX CytomX Therapeutics, Inc.
1.6699
-0.01%
 
FDMT 4D Molecular Therapeutics, Inc.
25.30
-4.13%
 
MRUS Merus N.V.
40.96
+1.25%
 
BCYC Bicycle Therapeutics plc
22.57
0.00%